ALK: a driver of cancer pathogenesis and progression1,2

ALK-mediated signaling may play an important role in the development and progression of NSCLC1-3

ALK diagram showing how ALK-mediated signaling may play an important role in NSCLC

Adapted by permission from Macmillan Publishers Ltd: Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther. 2014;95:15-23, copyright 2014.

AKT=AKT8 virus oncogene cellular homolog; ALK=anaplastic lymphoma kinase; BAD=bcl-2–associated death promoter protein; EML4=echinoderm microtubule-associated protein-like 4; ERK=extracellular signal-regulated kinase; IP3=inositol trisphosphate; MEK=mitogen-activated protein kinase/ERK kinase; mTOR=mammalian target of rapamycin; NSCLC=non-small cell lung cancer; PI3K=phosphatidylinositol 3-kinase; PIP2=phosphatidylinositol 3,4-bisphosphate; PLC-γ=phospholipase C-γ; Ras=rat sarcoma; S6K=S6 kinase; STAT3/5=signal transducer and activator of transcription 3/5.

References

  1. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199:330-358. PMID: 15095281
  2. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7:1466-1476. PMID: 19737969
  3. Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther. 2014;95:15-23. PMID: 24091716